In 2012, Sanofi Pasteur was competing to develop a vaccine against dengue, a mosquito-borne condition, and was investigating this product in a Phase IIb trial conducted with school kids in Thailand. But while the nominee vaccine matched a balanced immune response that was good and the high safety expectations,it had a proof of effectiveness of a mere 30%, far below the 70% mark the company had targeted.
Guillaume Leroy, vice president of the Dengue Company at Sanofi Pasteur, reflected on the way and the Phase IIb trial surprising outcome ahead. He had to decide whether to go ahead with the vaccine trials and generation, and if so, needed to create a strategic plan on how to price and deliver the vaccine for an instant roll out.
Sanofi Pasteur The Dengue Vaccine Dilemma case study solution
PUBLICATION DATE: April 28, 2014 PRODUCT #: 514074-PDF-ENG
This is just an excerpt. This case is about GLOBAL BUSINESS
Related Case Solutions & Analyses:
Global Dimension
Are social networking sites good recruitment sources
Facebook In 2013: Will Wall Street Hit Like the Like Button?
The New Mission for Multinationals
The Man in the Mirror (A)
Apple Inc. in 2015
The Business Development Manager
The First 10 Questions for Would-be Searchers
Note on Political Risk Analysis, Spanish Version
United States Agency for International Development (USAID): Campfire Program in Zimbabwe
